3-(t3-acetylphenyl)oxazolidin-2-one | 360580-22-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(t3-acetylphenyl)oxazolidin-2-one
• 英文别名: 3-(3-acetylphenyl)-2-oxazolidinone；3-(3-acetylphenyl)oxazolidin-2-one；3-[3-(acetyl)phenyl]-1,3-oxazolidine-2-one；3-(3-acetylphenyl)-1,3-oxazolidin-2-one
• CAS: 360580-22-9
• 化学式: C₁₁H₁₁NO₃
• mdl: MFCD13196269
• 分子量: 205.213
• InChiKey: VMYSEPFZMXONLL-UHFFFAOYSA-N

物化性质

• 沸点：
  354.6±21.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(t3-acetylphenyl)oxazolidin-2-one 在 溴 、 溶剂黄146 、 sodium thiosulfate 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以64%的产率得到3-[3-(bromoacetyl)phenyl]-1,3-oxazolidine-2-one
  参考文献：
  名称：

  WO2007/58504

  摘要：

  公开号：
• 作为产物：
  描述：

  2-唑烷酮 、 3'-溴苯乙酮 在 tris(dibenzylideneacetone)dipalladium (0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以60%的产率得到3-(t3-acetylphenyl)oxazolidin-2-one
  参考文献：
  名称：

  3-Aryl-2-oxazolidinones through the Palladium-Catalyzed N-Arylation of 2-Oxazolidinones

  摘要：

  [GRAPHICS]3-Aryl-2-oxazolidinones are obtained in good yields through the palladium-catalyzed N-arylation of 2-oxazolidinones with aryl bromides. The nature of aryl bromides, phosphine ligands, bases, and solvents strongly affects the reaction outcome.

  DOI：

  10.1021/ol016208m

文献信息

• [EN] QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS<br/>[FR] DERIVES DE QUINOLINE ET DE QUINAZOLINE PRESENTANT UNE AFFINITE VIS-A-VIS DES RECEPTEURS DU TYPE 5HT1
  申请人：GLAXO GROUP LTD

  公开号：WO2005014552A1

  公开（公告）日：2005-02-17

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药用盐：其中R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于抑郁症或焦虑等中枢神经系统疾病。
• Copper-Catalyzed One-Pot Synthesis of <i>N</i>-Aryl Oxazolidinones from Amino Alcohol Carbamates
  作者：William Mahy、Pawel K. Plucinski、Christopher G. Frost

  DOI：10.1021/ol502322c

  日期：2014.10.3

  sequential intramolecular cyclization of amino alcohol carbamates followed by Cu-catalyzed cross-coupling with aryl iodides under mild conditions has been developed. The reaction occurred in good yields and tolerated aryl iodides containing functionalities such as nitriles, ketones, ethers, and halogens. Heteroaryl iodides and substituted amino alcohol carbamates were also well tolerated.

  已经开发出在氨基甲酸酯氨基甲酸酯的有效顺序分子内环化，然后在温和条件下与芳基碘化物进行铜催化的交叉偶联。该反应以高收率进行，并且可以耐受含有官能团（例如腈，酮，醚和卤素）的芳基碘化物。杂芳基碘化物和取代的氨基醇氨基甲酸酯也被很好地耐受。
• Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
  申请人：Bergauer Markus

  公开号：US20060229312A1

  公开（公告）日：2006-10-12

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供式(I)的化合物和药学上可接受的盐：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。
• Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
  申请人：Glaxo Group Limited

  公开号：US07279481B2

  公开（公告）日：2007-10-09

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供化学式（I）的化合物及其药学上可接受的盐： 其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。
• QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS
  申请人：Bergauer Markus

  公开号：US20070167423A1

  公开（公告）日：2007-07-19

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药学上可接受的盐： 其中，R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中定义的那样。还公开了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病如抑郁症或焦虑症。